ARTICLE SUMMARY:
Boston Scientific’s planned $1.26 billion acquisition of Silk Road Medical will change the transcarotid intervention market by bringing Silk Road’s innovative transcarotid artery revascularization technology to more surgeons than ever before, especially outside the US.
Boston Scientific expects its recent acquisition of Silk Road Medical to help transform the entire carotid intervention market by putting its international marketing power behind Silk Road’s unique technology for transcarotid artery revascularization (TCAR).
